Chronic kidney disease (CKD) is common, largely silent, and serious. Most people who have the condition do not realize they ...
Chronic kidney disease (CKD) is common, largely silent and serious. Most people who have the condition do not realize they ...
Three therapeutic lines in development — SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists — highlighted at the 37th National Congress of the Spanish Diabetes Society Foundation (FSED), held ...
People with both type 2 diabetes and chronic kidney disease face a heart health double-whammy, a new study says. Men with both diabetes and kidney disease will develop heart health problems 28 years ...
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results